Jann N. Sarkaria

Mayo Clinic, Rochester

Research Area

Biography

Jann N. Sarkaria has not added Biography.
If you are Jann N. Sarkaria and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer research\| PubMed ID: 10485486	1999
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16609043	2006
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\| PubMed ID: 17762343	2007
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18483356	2008
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18559622	2008
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncology\| PubMed ID: 18952979	2009
Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in agg... Journal of neuropathology and experimental neurology\| PubMed ID: 19018242	2008
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular cancer therapeutics\| PubMed ID: 19174557	2009
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. International journal of radiation oncology, biology, physics\| PubMed ID: 19695438	2009
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. Journal of neuro-oncology\| PubMed ID: 20443131	2010
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiform... International journal of radiation oncology, biology, physics\| PubMed ID: 20864273	2011
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20921209	2010
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21300883	2011
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22675172	2012
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-oncology\| PubMed ID: 22711607	2012
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro-oncology\| PubMed ID: 23460322	2013
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24398046	2014
BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics\| PubMed ID: 24496381	2014
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24838527	2014
Design and characterization of an economical (192)Ir hemi-brain small animal irradiator. International journal of radiation biology\| PubMed ID: 24844370	2014
Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 24875464	2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-oncology\| PubMed ID: 25165194	2015
Critical functions of RhoB in support of glioblastoma tumorigenesis. Neuro-oncology\| PubMed ID: 25216671	2015
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Molecular cancer therapeutics\| PubMed ID: 25351918	2015
Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α. Neuro-oncology\| PubMed ID: 25468898	2015
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-oncology\| PubMed ID: 25526733	2015
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25609063	2015
Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PloS one\| PubMed ID: 25933216	2015
Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs. Scientific reports\| PubMed ID: 25962872	2015
Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro-oncology\| PubMed ID: 25972455	2015
Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma? Seminars in radiation oncology\| PubMed ID: 26050590	2015
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget\| PubMed ID: 26059434	2015
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 26111795	2015
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Neuro-oncology\| PubMed ID: 26136493	2016
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Frontiers in neuroscience\| PubMed ID: 26136652	2015
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. Journal of medicinal chemistry\| PubMed ID: 26331426	2015
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 26354993	2015
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-oncology\| PubMed ID: 26359209	2016
CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-oncology\| PubMed ID: 26403167	2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular cancer therapeutics\| PubMed ID: 26438157	2015
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26561558	2016
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance wi... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 26604245	2016
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute\| PubMed ID: 26615020	2016
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide. Molecular cancer research : MCR\| PubMed ID: 26764186	2016
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell reports\| PubMed ID: 26972001	2016
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. Journal of neurosurgery\| PubMed ID: 27177180	2017
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 27196784	2016
Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Scientific reports\| PubMed ID: 27354287	2016
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-oncology\| PubMed ID: 27370397	2016
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer research\| PubMed ID: 27793847	2017
Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. Journal of neurosurgery\| PubMed ID: 28059653	2017
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient... Oncotarget\| PubMed ID: 28178667	2017
Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. Biochemical and biophysical research communications\| PubMed ID: 28300555	2017
Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 28348210	2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-oncology\| PubMed ID: 28379424	2017
Challenges in the delivery of therapies to melanoma brain metastases. Current pharmacology reports\| PubMed ID: 28546917	2016
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature neuroscience\| PubMed ID: 28604685	2017
Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacological research\| PubMed ID: 28634084	2017
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastom... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 28847917	2017
Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 28912141	2017
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 28947502	2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-oncology\| PubMed ID: 29016887	2018
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-oncology\| PubMed ID: 29016900	2018
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer cell\| PubMed ID: 29198914	2017
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer\| PubMed ID: 29313954	2018
LPA signaling is regulated through the primary cilium: a novel target in glioblastoma. Oncogene\| PubMed ID: 29321663	2018
Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 29437873	2018
Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 29440450	2018
Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival. Molecular and cellular biology\| PubMed ID: 29483302	2018
Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. PloS one\| PubMed ID: 29566069	2018
Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome biology\| PubMed ID: 29587824	2018
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. Neuro-oncology\| PubMed ID: 29660019	2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute\| PubMed ID: 29788332	2018
H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. eLife\| PubMed ID: 29932419	2018
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Molecular cancer therapeutics\| PubMed ID: 29970480	2018
Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharmaceutical research\| PubMed ID: 30003344	2018
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nature communications\| PubMed ID: 30054476	2018
A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nature communications\| PubMed ID: 30082792	2018
Hypoxia-inducible factor 2α: a novel target in gliomas. Future medicinal chemistry\| PubMed ID: 30089425	2018
Investigating Dependencies of Relative Biological Effectiveness for Proton Therapy in Cancer Cells. International journal of particle therapy\| PubMed ID: 30159358	2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular cancer therapeutics\| PubMed ID: 30166399	2018
IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell communication and signaling : CCS\| PubMed ID: 30231881	2018
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 30266764	2019
Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system. The British journal of radiology\| PubMed ID: 30299986	2019
Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Frontiers in materials\| PubMed ID: 30581816	2018
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 30622172	2019
Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and -Deficient Mice. Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 30705084	2019
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Frontiers in oncology\| PubMed ID: 30723695	2018
Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells. PloS one\| PubMed ID: 30811507	2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCC... Journal of neuro-oncology\| PubMed ID: 31119479	2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-oncology\| PubMed ID: 31121035	2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N027... Journal of neuro-oncology\| PubMed ID: 31165953	2019
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. Cancer research\| PubMed ID: 31273061	2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-oncology\| PubMed ID: 31276167	2019
ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach. American journal of clinical oncology\| PubMed ID: 31343422	2019
Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-oncology\| PubMed ID: 31346613	2019
Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens. Biomaterials\| PubMed ID: 31352310	2019
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro-oncology\| PubMed ID: 31363754	2019
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro-oncology\| PubMed ID: 31433055	2020
Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 31570001	2019
Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 31619389	2019
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. Molecular medicine (Cambridge, Mass.)\| PubMed ID: 31726966	2019
Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal. Frontiers in oncology\| PubMed ID: 31781508	2019
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31852831	2020
Imaging and Dosimetry Study of Inter-fraction Setup Error in a Murine Xenograft Flank Tumor Radiation Model. Radiation research\| PubMed ID: 31877254	2020
Evaluating infusate parameters for direct drug delivery to the brainstem: a comparative study of convection-enhanced delivery versus osmotic pump delivery. Neurosurgical focus\| PubMed ID: 31896090	2020
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. PloS one\| PubMed ID: 32218600	2020
Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. Scientific reports\| PubMed ID: 32300151	2020
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery... Neuro-oncology\| PubMed ID: 32506123	2020
Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity". Neuro-oncology\| PubMed ID: 32556220	2020
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nature communications\| PubMed ID: 32732914	2020
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Molecular cancer therapeutics\| PubMed ID: 32796101	2020
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Scientific reports\| PubMed ID: 32938997	2020
Quantifying Glioblastoma Drug Response Dynamics Incorporating Treatment Sensitivity and Blood Brain Barrier Penetrance From Experimental Data. Frontiers in physiology\| PubMed ID: 32973540	2020
ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nature communications\| PubMed ID: 33203881	2020
Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model. Journal of neuroinflammation\| PubMed ID: 33208156	2020
Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies. Cancers\| PubMed ID: 33256106	2020
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas. BMC cancer\| PubMed ID: 33302912	2020
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. Pharmaceutics\| PubMed ID: 33322488	2020
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood\| PubMed ID: 33507295	2021
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer research\| PubMed ID: 33597272	2021
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. Oncogene\| PubMed ID: 33707748	2021
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. Molecular medicine (Cambridge, Mass.)\| PubMed ID: 33765907	2021
Efficacy of Tesevatinib in -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Molecular cancer therapeutics\| PubMed ID: 33785646	2021
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer research\| PubMed ID: 34016623	2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-oncology\| PubMed ID: 34050676	2021
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. Neuro-oncology\| PubMed ID: 34107029	2021
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Communications biology\| PubMed ID: 34112916	2021
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro-oncology\| PubMed ID: 34232318	2022
Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models. Journal of neuroscience methods\| PubMed ID: 34390758	2021
Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. International journal of radiation oncology, biology, physics\| PubMed ID: 34400266	2021
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 34433651	2021
Matrix Hyaluronic Acid and Hypoxia Influence a CD133 Subset of Patient-Derived Glioblastoma Cells. Tissue engineering. Part A\| PubMed ID: 34435883	2022
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. International journal of radiation oncology, biology, physics\| PubMed ID: 34454045	2021
Changes in the vasculature of human brain tumors: Implications for treatment. Neuro-oncology\| PubMed ID: 34515316	2021
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 34556535	2021
Protein kinase C and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell reports\| PubMed ID: 34818553	2021
The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. Scientific reports\| PubMed ID: 34862404	2021
Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor. Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 34887255	2022
massNet: integrated processing and classification of spatially resolved mass spectrometry data using deep learning for rapid tumor delineation. Bioinformatics (Oxford, England)\| PubMed ID: 35040929	2022
The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma. PloS one\| PubMed ID: 35134075	2022
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. Molecular cancer research : MCR\| PubMed ID: 35191501	2022
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro-oncology\| PubMed ID: 35231103	2022
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 35370138	2022
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Science advances\| PubMed ID: 35486732	2022
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics\| PubMed ID: 35631512	2022
EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. Nature cell biology\| PubMed ID: 35915159	2022
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-oncology\| PubMed ID: 35973817	2023
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 36071925	2022
Perivascular Stromal Cells Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model. Advanced science (Weinheim, Baden-Wurttemberg, Germany)\| PubMed ID: 36109186	2022
Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 36137710	2022
Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. Cancers\| PubMed ID: 36428586	2022
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nature cancer\| PubMed ID: 36732634	2023
Main Manuscript for Cell migration simulator-based biomarkers for glioblastoma. bioRxiv : the preprint server for biology\| PubMed ID: 36865270	2023
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neuro-oncology advances\| PubMed ID: 37324218	2023
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas. Communications biology\| PubMed ID: 37340056	2023
A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma. JCI insight\| PubMed ID: 37427593	2023
MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. Biomedicines\| PubMed ID: 37509518	2023
How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors. Pharmaceutical research\| PubMed ID: 37589827	2023
Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients. Neuro-oncology advances\| PubMed ID: 37638345	2023
CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance. International journal of oncology\| PubMed ID: 37654190	2023
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 37773633	2024
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 37828724	2024
GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress. Cancer discovery\| PubMed ID: 37902550	2024
Differential HO Metabolism among Glioblastoma Subtypes Confers Variable Responses to Pharmacological Ascorbate Therapy Combined with Chemoradiation. International journal of molecular sciences\| PubMed ID: 38138986	2023
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts. Molecular cancer therapeutics\| PubMed ID: 38224566	2024
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Science translational medicine\| PubMed ID: 38354228	2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 38743766	2024
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-oncology\| PubMed ID: 38770568	2024
Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 38858089	2024
The impact of ATP-binding cassette transporters in the diseased brain: Context matters. Cell reports. Medicine\| PubMed ID: 38897176	2024
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nature communications\| PubMed ID: 38906885	2024
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse? Neuro-oncology\| PubMed ID: 39081224	2024
Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma. Cancer research communications\| PubMed ID: 39087397	2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of ... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 39284626	2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Molecular cancer therapeutics\| PubMed ID: 39440433	2025
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA oncology\| PubMed ID: 39480453	2024
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628. Molecular cancer therapeutics\| PubMed ID: 39559836	2025
Cell migration simulator-based biomarkers for glioblastoma. Neuro-oncology advances\| PubMed ID: 39605317	2024
Glutathione peroxidase 4 overexpression induces anomalous subdiffusion and impairs glioblastoma cell growth. Journal of biological engineering\| PubMed ID: 39709480	2024
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review. JAMA oncology\| PubMed ID: 39724142	2025
A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery. Neuro-oncology\| PubMed ID: 39786485	2025
Recurrent adamantinomatous craniopharyngioma stabilized with tocilizumab and bevacizumab: illustrative case. Journal of neurosurgery. Case lessons\| PubMed ID: 39805108	2025
selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model. NAR cancer\| PubMed ID: 39968526	2025
Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. EMBO molecular medicine\| PubMed ID: 39972068	2025
The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-oncology\| PubMed ID: 40163716	2025
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-oncology\| PubMed ID: 40230030	2025
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS. bioRxiv : the preprint server for biology\| PubMed ID: 40462892	2025
Methods for cell- and tissue-specific DNA aptamer selection. Molecular therapy. Methods & clinical development\| PubMed ID: 40469753	2025
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. Neuro-oncology\| PubMed ID: 40579995	2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma. Acta neuropathologica communications\| PubMed ID: 40581663	2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 40591434	2025
Analysis of imaging signatures in F-DOPA PET of glioblastoma treated with dose-escalated radiotherapy. Frontiers in oncology\| PubMed ID: 40881875	2025
Rewiring of cortical glucose metabolism fuels human brain cancer growth. Nature\| PubMed ID: 40903569	2025
XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in wildtype glioblastoma. Frontiers in oncology\| PubMed ID: 41064076	2025
Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas. JCI insight\| PubMed ID: 41066183	2025
Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. Journal of translational medicine\| PubMed ID: 41121224	2025
Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma. Scientific reports\| PubMed ID: 41125665	2025
Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on F-DOPA PET Images. Cancers\| PubMed ID: 41228352	2025
Digital twins for in vivo metabolic flux estimations in patients with brain cancer. Cell metabolism\| PubMed ID: 41330373	2026
Optimizing procedures for ocular radiation injury studies in the tree shrew. Exploration of targeted anti-tumor therapy\| PubMed ID: 41357135	2025
Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations. Nature communications\| PubMed ID: 41501023	2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 41664821	2026